The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | MRD positivity and associated reduction in MM PFS
Jesús San Miguel
• 14 Sep 2019
Jesus San Miguel, MD, of The Univeristy of Navarra Clinic, Pamplona, Spain, discusses the longer survival of measurable residual disease (MRD) negative patients compared to MRD positive, and the best methods for studying lesions. This interview was recorded at the International Myeloma Workshop, in Boston, MA.
